Lilly To Partner With Indian Drug Makers In Wake Of Patent Protection (India)
This article was originally published in PharmAsia News
Executive Summary
Eli Lilly is engaging in joint ventures with Indian pharmaceuticals to take advantage of their move to research and development and away from generics. U.S.-based Lilly's CEO said his company is interested in getting involved in global trials with companies that develop their own drugs as far as the Phase III stage. Sidney Taurel also said India's adoption of new patent protections is welcomed by firms such as his. Among companies Taurel mentioned were Jubilant Biosys, Nicholas Piramal India and Suven Pharmaceuticals. (Click here for more
You may also be interested in...
Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.